An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects with Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
Latest Information Update: 29 May 2025
At a glance
- Drugs Bupropion/dextromethorphan (Primary)
- Indications Dementia
- Focus Adverse reactions; Registrational
- Sponsors Axsome Therapeutics
Most Recent Events
- 22 May 2025 Status changed from recruiting to discontinued.
- 20 Dec 2024 New trial record